Lexaria Bioscience receives cannabis R&D license from Health Canada
Lexaria Bioscience announced that its subsidiary, Lexaria CanPharm ULC., has been issued a cannabis Research and Development license by Health Canada with a four-year term until August 9, 2023 unless renewed. Lexaria said the new cannabis R&D license is effective immediately and "will allow one of the country's newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECH infusions as well as including two different methodologies by which the company can create nano-sized molecules when deemed beneficial and is currently operational." "Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company's history," said John Docherty, President and Chief Scientist of Lexaria. "This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada's licensed cannabis companies."